RxDoctor Payments Data

Gary Woodall, MD

Internal Medicine · San Diego, CANPI 1427168301

Payments from drug & device makers

$2,661in general payments, 2019–2025

Across 268 payments — averaging $9.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$1K
  • Viiv Healthcare Company$682
  • Johnson & Johnson$266
  • EMD Serono, Inc.$229
  • Merck$100
  • GSK$88
  • plus $115 from 3 others

What the payments were for

  • Food & beverage$2,58697%
  • Education$753%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead171$1,182
Viiv Healthcare Company42$682
Johnson & Johnson29$266
EMD Serono, Inc.13$229
Merck6$100
GSK4$88
Janssen Products, LP1$75
Mylan Institutional Inc.1$23
Theratechnologies Inc.1$18

How this compares

$2,661 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$58,436
Medicare patients
121
Services billed
642

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala175$732,394
SerostimSomatropin13$242,925
OdefseyEmtricitab/Rilpiviri/Tenof Ala47$199,195
DescovyEmtricitabine/Tenofov Alafenam70$163,968
TriumeqAbacavir/Dolutegravir/Lamivudi30$132,310
GenvoyaElviteg/Cob/Emtri/Tenof Alafen19$130,295
PrezcobixDarunavir/Cobicistat38$104,265
JulucaDolutegravir/Rilpivirine24$81,641
DovatoDolutegravir Sodium/Lamivudine25$73,795
OzempicSemaglutide50$56,959
IsentressRaltegravir Potassium23$44,324
JardianceEmpagliflozin39$24,508
JanuviaSitagliptin Phosphate24$24,507
PrezistaDarunavir12$22,988
EvotazAtazanavir Sulfate/Cobicistat13$19,534

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy, Genvoya$1,182$1,026,657264 claims
Viiv Healthcare CompanyTriumeq, Juluca, Dovato$682$287,74779 claims
EMD Serono, Inc.Serostim$229$242,92513 claims
Johnson & JohnsonPrezcobix$266$104,26538 claims
MerckIsentress, Januvia$100$68,83247 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →